(Q28362951)

English

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

scientific article

In more languages

Statements

scholarly article

0 references

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG) (English)

0 references

phase III clinical trial

0 references

multicenter clinical trial

0 references

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Hauschild

1

0 references

C Garbe

2

0 references

W Stolz

3

0 references

U Ellwanger

4

0 references

S Seiter

5

0 references

R Dummer

6

0 references

S Ugurel

7

0 references

G Sebastian

8

0 references

D Nashan

9

0 references

R Linse

10

0 references

W Achtelik

11

0 references

P Mohr

12

0 references

R Kaufmann

13

0 references

M Fey

14

0 references

J Ulrich

15

0 references

W Tilgen

16

0 references

language of work or name

0 references

publication date

20 April 2001

0 references

British Journal of Cancer

0 references

84

0 references

8

0 references

1036-42

0 references

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

20 March 2017

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

7 April 2017

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

29 September 2017

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

29 September 2017

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

29 September 2017

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

29 September 2017

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

29 September 2017

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

29 September 2017

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

2 June 2018

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

2 June 2018

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

2 June 2018

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

2 June 2018

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

2 June 2018

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

27 November 2018

Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

27 November 2018

The use of interferon-alpha in the treatment of cutaneous melanoma: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363865

27 November 2018

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemoimmunotherapy of melanoma. Is it time for phase III trials?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11308250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.2001.1731

0 references

Dimensions Publication ID

0 references

0 references

0 references

ResearchGate publication ID

0 references

Springer Nature article ID

10.1054/bjoc.2001.1731

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28362951&oldid=1956207346"